1月20日 - ** 法国炎症性疾病专家AbivaxABVX.PA股价上涨6%，收窄了早些时候约8%的涨幅；分析师认为，这只普遍波动的股票的上涨与另一篇激起并购讨论的媒体报道有关。
** Kepler Chevreux和ODDO BHF的分析师将股价上涨与《La Lettre》的一篇报道联系在一起，该报道称英国制药集团阿斯利康AZN.L在2025年底为每股Abivax股票出价约176欧元($205.85)
** 最近围绕 Abivax 的并购传闻越来越多
** La Lettre早些时候报道称，竞争对手礼来LLY.N正准备以150亿欧元(合175亿美元)，但法国财政部表示尚未收到 (link) 任何正式的投资审批申请。
** 阿斯利康和阿比瓦克斯公司没有立即发表评论。
(1 美元 = 0.8550 欧元)
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.